CordenPharma Appoints Jean-Luc Herbeaux

CordenPharma announced a leadership change on September 15, 2026. CordenPharma appointed former Hovione CEO Jean-Luc Herbeaux to succeed Michael Quirmbach and lead execution of the CDMO’s long-term strategy, with a focus on continued growth.

What changed

Jean-Luc Herbeaux was named Chief Executive Officer. Michael Quirmbach, who has served as CordenPharma’s Chief Executive Officer since 2019, will remain actively involved with the company as a Board Member and Senior Advisor.

Leader: Jean-Luc Herbeaux
Role: Chief Executive Officer
Effective: 1 October 2026
Announcement date: September 15, 2026

Leadership background

Herbeaux joins CordenPharma from Hovione, an international CDMO, where he served as Chief Executive Officer for more than four years. Before becoming CEO, he was Chief Operating Officer at Hovione and previously held several senior roles at Evonik.

The mandate

CordenPharma said Herbeaux will lead the execution of the company’s long-term strategy, working with the Board and with continued support from Astorg. The company named continued growth, operational execution, and customer delivery as focus areas.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

Primary source: CordenPharma leadership announcement.